Benjamin Musher is an Oncology physician affiliated with Baylor College of Medicine. OpenAlex indexes 83 publications with 2,474 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1504 Taub Loop
Houston, TX 770301608
Telephone
173-798-8890Provider last certified this registry record 16 Sept 2024.
Clinical trials
- Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Sponsor: Diakonos Oncology Corporation
- TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
- Johnson & Johnson Health Care Systems Inc.Program year20251 payment
- Exelixis Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42.4%Serotonin-3 Receptor Antagonist23.7%Ondansetron Hcl100%Part D≥12 patientsAntidiarrheal microorganisms18.6%Creon100%Part D<11 patientsRespiratory
35.6%Opioid Agonist35.6%Hydrocodone-Acetaminophen100%Part D<11 patientsNervous system
22%Atypical Antipsychotic22%Olanzapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Unmet supportive care needs in patients with advanced cancer and its impact on distress
BMC Palliative Care
2025 - 590 Vaccination by homologous antigenic loading as adjuvant therapy for glioblastoma: correlation of immune response and early efficacy signal with vaccine cell gene signature
Regular and Young Investigator Award Abstracts
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Christie Ballantyne, MD
Baylor College of Medicine
Biykem Bozkurt, MD
Baylor College of Medicine
William Mitch, MD
Baylor College of Medicine
Garabed Eknoyan, MD
Baylor College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”